Breaking News

Repligen Acquires 908 Devices’ Bioprocess Analytics Portfolio

Includes PAT devices for real-time process monitoring, control and analysis.

repligen logo and 908 devices logo

Repligen Corporation, a life sciences company, has acquired 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies. Products acquired from 908 Devices include: MAVERICK and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters